Literature DB >> 15688423

Evidence for inactivation of distinct telomerase repressor genes in different types of human cancers.

Hiromi Tanaka1, Izumi Horikawa, J Carl Barrett, Mitsuo Oshimura.   

Abstract

Telomerase activation, a critical event in human carcinogenesis, may result from defects in telomerase-repressing mechanisms. Data from microcell-mediated chromosome transfer (MMCT) suggests the presence of telomerase repressor genes that become inactivated during carcinogenic processes. The transfer of a normal human chromosome 3 represses telomerase activity of both human renal cell carcinoma (RCC) and breast carcinoma (BC) cells. For a genetic complementation analysis of telomerase repression, 2 RCC cell lines (KC12 and RCC23) and a BC cell line (21NT) were used to make somatic cell hybrids. All of the self-hybrids (KC12 x KC12 and 21NT x 21NT) and hybrids from 2 RCC cell lines (KC12 x RCC23) expressed the telomerase activity similarly to their parental cells, excluding the possibility of a ploidy-associated change in telomerase activity and suggesting the same genetic defect shared by the 2 RCC cell lines. In contrast, the fusion of BC and RCC cells (21NT x KC12 and 21NT x RCC23) produced a significant number of telomerase-negative hybrids, suggesting that the RCC and BC cells have different defects in the telomerase repression, which are functionally corrected through genetic complementation in the hybrids. This notion was supported by the mapping of the RCC telomerase repressor gene to a 5.7-Mb region on 3p21, which is different from the candidate region for the BC telomerase repressor gene on the same chromosomal band. These findings provide direct evidence for inactivation of distinct telomerase repressor genes in different types of human cancers and may have implications in the tissue-specific regulation of telomerase during human development and carcinogenesis. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688423     DOI: 10.1002/ijc.20879

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  The manipulation of chromosomes by mankind: the uses of microcell-mediated chromosome transfer.

Authors:  Karen J Meaburn; Christopher N Parris; Joanna M Bridger
Journal:  Chromosoma       Date:  2005-10-15       Impact factor: 4.316

Review 2.  Telomere biology in Metazoa.

Authors:  Nuno M V Gomes; Jerry W Shay; Woodring E Wright
Journal:  FEBS Lett       Date:  2010-07-23       Impact factor: 4.124

3.  Localization of an hTERT repressor region on human chromosome 3p21.3 using chromosome engineering.

Authors:  Satoshi Abe; Hiromi Tanaka; Tomomi Notsu; Shin-Ichi Horike; Chikako Fujisaki; Dong-Lai Qi; Takahito Ohhira; David Gilley; Mitsuo Oshimura; Hiroyuki Kugoh
Journal:  Genome Integr       Date:  2010-05-26

4.  The untapped potential of reptile biodiversity for understanding how and why animals age.

Authors:  Luke A Hoekstra; Tonia S Schwartz; Amanda M Sparkman; David A W Miller; Anne M Bronikowski
Journal:  Funct Ecol       Date:  2019-09-09       Impact factor: 5.608

5.  Stress-related changes in leukocyte profiles and telomere shortening in the shortest-lived tetrapod, Furcifer labordi.

Authors:  Falk Eckhardt; Angela Pauliny; Nicky Rollings; Frank Mutschmann; Mats Olsson; Cornelia Kraus; Peter M Kappeler
Journal:  BMC Evol Biol       Date:  2020-12-01       Impact factor: 3.260

6.  Functional role of SETD2, BAP1, PARP-3 and PBRM1 candidate genes on the regulation of hTERT gene expression.

Authors:  Hannah Linne; Hemad Yasaei; Alison Marriott; Amanda Harvey; Kefah Mokbel; Robert Newbold; Terry Roberts
Journal:  Oncotarget       Date:  2017-06-27

7.  Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer.

Authors:  Takuki Yagyu; Takahito Ohira; Ryutaro Shimizu; Masaki Morimoto; Yuki Murakami; Takehiko Hanaki; Kyoichi Kihara; Tomoyuki Matsunaga; Manabu Yamamoto; Naruo Tokuyasu; Teruhisa Sakamoto; Yoshiyuki Fujiwara; Hiroyuki Kugoh
Journal:  Sci Rep       Date:  2021-07-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.